While many updates to Tesla vehicles are fixed via software updates not requiring a visit to a repair shop, the transistor issue, like four of the other recalls, requires an on-site fix.
Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics ...